{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:03:26Z","timestamp":1776938606716,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Real-world data are needed to inform clinical practice with regards to anticoagulation treatment for persons with venous thromboembolism (VTE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To identify the type and duration of antithrombotic treatment in persons with VTE. Anticoagulation dosage and persistence\/adherence were among the secondary objectives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A multicenter, observational, prospective study conducted in Greek adults with VTE with two on-site visits -baseline and at three months- and a telephone follow-up at 6 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 600 eligible persons were enrolled. The index event was \u2018PE only\u2019 in 50%, \u2018DVT only\u2019 in 40%, and \u2018DVT+PE\u2019 in 10%. Risk factors were categorized as temporary major (21%), temporary minor (37%), and persistent (43%), with active cancer present in 18% of patients. All VTE patients received anticoagulants: 73% received oral anticoagulants (72% DOACs, 1% VKAs) and 70% received parenteral anticoagulants. Treatment was oral only in 30%, parenteral only in 27%, and both in 43%. The most common DOAC was apixaban (47%). Extended anticoagulation (&gt;6 months) was administered to 41% with only 9% (18\/198) of those on DOACs receiving a reduced dose. Persistent risk factors predicted extended anticoagulation, while diabetes, COVID-19, and temporary minor risk factors did not. Adherence\/persistence rates were similar between DOAC and non-DOAC-treated patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>VTE was mainly treated with a combination of parenteral and oral anticoagulants. DOACs, primarily apixaban, were the most common oral treatments. Forty percent of patients received extended anticoagulation, mostly at standard dosages. Adherence and persistence rates were high for both DOAC and non-DOAC treatments.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12959-025-00749-1","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:28:33Z","timestamp":1750663713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u0391 6-month, multicenter, observational study investigating the treatment of venous thromboembolism in Greece (VICTORIA study)"],"prefix":"10.1186","volume":"23","author":[{"given":"Paraskevi","family":"Savvari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Skiadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenia","family":"Mavrokefalou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Kakkos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioulia","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios A.","family":"Pitoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effrosyni","family":"Dima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Ferdoutsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Ntaios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Giannoukas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ourania","family":"Kotsiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Tsoukalas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Staramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Filis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Savopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kakisis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Tzilalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Koulouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theophanis","family":"Papas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Skrapari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damianos","family":"Menegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The VICTORIA Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kalomenidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foteini","family":"Malli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Meletis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Nikolakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios A.","family":"Chatzelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Sagris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Karathanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kaparelou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilektra","family":"Voulgareli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Kyriakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Theodoridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian Filippas","family":"Ntekouan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464\u201374.","journal-title":"Nat Rev Cardiol"},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1160\/TH07-03-0212","volume":"98","author":"AT Cohen","year":"2007","unstructured":"Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756\u201364.","journal-title":"Thromb Haemost."},{"key":"749_CR3","first-page":"1901647","volume":"54","author":"SV Konstantinides","year":"2019","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019;54:1901647.","journal-title":"The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)"},{"key":"749_CR4","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1093\/eurheartj\/ehx003","volume":"39","author":"L Mazzolai","year":"2017","unstructured":"Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2017;39:4208\u201318.","journal-title":"Eur Heart J"},{"key":"749_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing G-J, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160:2247\u201359.","journal-title":"Chest"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927\u201374.","journal-title":"Blood Adv"},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34:452\u201367.","journal-title":"Ann Oncol"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.thromres.2014.05.035","volume":"134","author":"ES Mearns","year":"2014","unstructured":"Mearns ES, Kohn CG, Song JS, Hawthorne J, Meng J, White CM, et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res. 2014;134:310\u20139.","journal-title":"Thromb Res"},{"key":"749_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1503\/cmaj.080171","volume":"179","author":"N Oake","year":"2008","unstructured":"Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179:235\u201344.","journal-title":"CMAJ"},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/jth.12086","volume":"11","author":"RA Rodriguez","year":"2013","unstructured":"Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost. 2013;11:390\u20134.","journal-title":"J Thromb Haemost"},{"key":"749_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12614","volume":"5","author":"V Speed","year":"2021","unstructured":"Speed V, Auyeung V, Patel JP, Cooper D, Miller S, Roberts LN, et al. Adherence to rivaroxaban for the treatment of venous thromboembolism-Results from the FIRST registry. Res Pract Thromb Haemost. 2021;5: e12614.","journal-title":"Res Pract Thromb Haemost"},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1007\/s12325-022-02391-z","volume":"40","author":"M Alberts","year":"2023","unstructured":"Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, et al. Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study. Adv Ther. 2023;40:1750\u201364.","journal-title":"Adv Ther"},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.thromres.2015.02.001","volume":"135","author":"W Ageno","year":"2015","unstructured":"Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res. 2015;135:666\u201372.","journal-title":"Thromb Res"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.thromres.2019.10.003","volume":"183","author":"MA de Winter","year":"2019","unstructured":"de Winter MA, Remme GCP, Kaasjager K, Nijkeuter M. Short-term versus extended anticoagulant treatment for unprovoked venous thromboembolism: A survey on guideline adherence and physicians\u2019 considerations. Thromb Res. 2019;183:49\u201355.","journal-title":"Thromb Res"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/imj.13382","volume":"47","author":"R Wallace","year":"2017","unstructured":"Wallace R, Anderson MA, See K, Gorelik A, Irving L, Manser R. Venous thromboembolism management practices and knowledge of guidelines: a survey of Australian haematologists and respiratory physicians. Intern Med J. 2017;47:436\u201346.","journal-title":"Intern Med J"},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/rth2.12014","volume":"1","author":"V Ten Cate","year":"2017","unstructured":"Ten Cate V, Prins MH. Secondary prophylaxis decision-making in venous thromboembolism: interviews on clinical practice in thirteen countries. Res Pract Thromb Haemost. 2017;1:41\u20138.","journal-title":"Res Pract Thromb Haemost"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1524-4733.2008.00400.x","volume":"12","author":"S Kripalani","year":"2009","unstructured":"Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12:118\u201323.","journal-title":"Value Health"},{"key":"749_CR18","unstructured":"Eliquis : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis# . Accessed 08 Jan 2025."},{"key":"749_CR19","unstructured":"Xarelto : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto . Accessed 08 Jan 2025."},{"key":"749_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.18549\/PharmPract.2019.3.1539","volume":"17","author":"F Allahwerdy","year":"2019","unstructured":"Allahwerdy F, Pan S, Feehan M, Jones AE, Munger MA, Witt DM. A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism. Pharm Pract (Granada). 2019;17:1539.","journal-title":"Pharm Pract (Granada)"},{"key":"749_CR21","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/jth.14548","volume":"17","author":"S Haas","year":"2019","unstructured":"Haas S, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, et al. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. J Thromb Haemost. 2019;17:1694\u2013706.","journal-title":"J Thromb Haemost"},{"key":"749_CR22","first-page":"144","volume":"23","author":"P Ioannou","year":"2019","unstructured":"Ioannou P, Kladou E. Anticoagulation management in deep venous thrombosis - real world data and unmet needs. Hippokratia. 2019;23:144.","journal-title":"Hippokratia"},{"key":"749_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620945792","author":"E Antonucci","year":"2020","unstructured":"Antonucci E, Migliaccio L, Abbattista M, Caronna A, De Marchi S, Di Giorgio A, et al. Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register. Clin Appl Thromb Hemost. 2020. https:\/\/doi.org\/10.1177\/1076029620945792.","journal-title":"Clin Appl Thromb Hemost"},{"key":"749_CR24","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1160\/TH16-10-0793","volume":"117","author":"AT Cohen","year":"2017","unstructured":"Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost. 2017;117:1326\u201337.","journal-title":"Thromb Haemost."},{"key":"749_CR25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.clinthera.2021.04.017","volume":"43","author":"W Ghanima","year":"2021","unstructured":"Ghanima W, Schultze A, Donaldson R, Brodin E, Halvorsen S, Graham S, et al. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns. Clin Ther. 2021;43:1179-90.e3.","journal-title":"Clin Ther"},{"key":"749_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4059","volume":"6","author":"GS Iyer","year":"2023","unstructured":"Iyer GS, Tesfaye H, Khan NF, Zakoul H, Bykov K. Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010\u20132020. JAMA Netw Open. 2023;6: e234059.","journal-title":"JAMA Netw Open"},{"key":"749_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2217\/fca-2019-0003","volume":"15","author":"SV Ramagopalan","year":"2019","unstructured":"Ramagopalan SV, Carroll R, Ulvestad M, Mehmud F, Alikhan R. The changing face of venous thromboembolism management in England. Future Cardiol. 2019;15:183\u20135.","journal-title":"Future Cardiol"},{"key":"749_CR28","unstructured":"European Pharmaceutical Review. Bayer\u2019s Xarelto\u00ae approved in the EU for the prevention of stroke in patients (20 December 2011). https:\/\/www.europeanpharmaceuticalreview.com\/news\/10555\/bayers-xarelto-approved-in-the-eu-for-the-prevention-of-stroke-in-patients-with-af\/ . Accessed 08 Jan 2025."},{"key":"749_CR29","unstructured":"Pfizer. European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE (Press release, 29 July 2014). https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european_commission_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_prevention_of_recurrent_dvt_and_pe . Accessed 08 Jan 2025."},{"key":"749_CR30","unstructured":"Johnson & Johnson. FDA Approves XARELTO\u00ae (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events (Press release, 02 November 2012). https:\/\/www.jnj.com\/media-center\/press-releases\/fda-approves-xarelto-rivaroxaban-to-treat-deep-vein-thrombosis-and-pulmonary-embolism-and-to-reduce-the-risk-of-recurrent-events . Accessed 08 Jan 2025."},{"key":"749_CR31","unstructured":"Pfizer. U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy (Press release, 21 August 2014). https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_the_risk_of_recurrent_dvt_and_pe_following_initial_therapy . Accessed 08 Jan 2025."},{"key":"749_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ijcard.2017.10.097","volume":"257","author":"L Keller","year":"2018","unstructured":"Keller L, Marten S, Hecker J, Sahin K, Tittl L, Beyer-Westendorf J. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry. Int J Cardiol. 2018;257:276\u201382.","journal-title":"Int J Cardiol"},{"key":"749_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11239-022-02641-5","volume":"54","author":"M Williams","year":"2022","unstructured":"Williams M, Ahuja T, Raco V, Papadopoulos J, Green D, Yuriditsky E, et al. Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients. J Thromb Thrombolysis. 2022;54:219\u201329.","journal-title":"J Thromb Thrombolysis"},{"key":"749_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1160\/TH16-07-0494","volume":"117","author":"J Trujillo-Santos","year":"2017","unstructured":"Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, D\u00edaz-Peromingo JA, N\u00fa\u00f1ez MJ, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost. 2017;117:382\u20139.","journal-title":"Thromb Haemost"},{"key":"749_CR35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s11239-019-01904-y","volume":"48","author":"JA Saunders","year":"2019","unstructured":"Saunders JA, Gustafson WL, Vazquez SR, Jones AE, Witt DM. Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism. J Thromb Thrombolysis. 2019;48:506\u201310.","journal-title":"J Thromb Thrombolysis"},{"key":"749_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.thromres.2017.07.029","volume":"157","author":"R Bauersachs","year":"2017","unstructured":"Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, et al. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017;157:181\u20138.","journal-title":"Thromb Res"},{"key":"749_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.06.006","volume":"31","author":"MS Al Yami","year":"2023","unstructured":"Al Yami MS, Qudayr AH, Alhushan LM, Hakami FM, Korayem GB, Alshaya OA, et al. Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study. Saudi Pharm J. 2023;31: 101673.","journal-title":"Saudi Pharm J"},{"key":"749_CR38","doi-asserted-by":"crossref","unstructured":"Di Micco P, Salazar VR, Capitan CF, Dentali F, Cuervo CG, Torres JLF, et al. Rivaroxaban Monotherapy in Patients with Pulmonary Embolism: Off-Label vs. Labeled Therapy. Life (Basel). 2022;12:1128.","DOI":"10.3390\/life12081128"},{"key":"749_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040449","volume":"10","author":"G Palareti","year":"2020","unstructured":"Palareti G, Antonucci E, Legnani C, Mastroiacovo D, Poli D, Prandoni P, et al. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. BMJ Open. 2020;10: e040449.","journal-title":"BMJ Open"},{"key":"749_CR40","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1001\/jama.2012.5034","volume":"307","author":"G De Berardis","year":"2012","unstructured":"De Berardis G, Lucisano G, D\u2019Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286\u201394.","journal-title":"JAMA"},{"key":"749_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/eb-2012-100951","volume":"16","author":"S Butalia","year":"2013","unstructured":"Butalia S, Leung AA. Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding. Evid Based Nurs. 2013;16:55\u20136.","journal-title":"Evid Based Nurs"},{"key":"749_CR42","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jgh.12190","volume":"28","author":"YL Peng","year":"2013","unstructured":"Peng YL, Leu HB, Luo JC, Huang CC, Hou MC, Lin HC, et al. Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study. J Gastroenterol Hepatol. 2013;28:1295\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"749_CR43","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s11239-017-1473-5","volume":"43","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Zhai Z, Yang Y, Wan J, Xie W, Zhu J, et al. Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a \u201creal-world\u201d study. J Thromb Thrombolysis. 2017;43:540\u20139.","journal-title":"J Thromb Thrombolysis"},{"key":"749_CR44","doi-asserted-by":"crossref","unstructured":"Cavallari I, Sagazio E, Antonucci E, Calabro' P, Gragnano F, Cirillo P, et al. Ischemic and bleeding risk stratification in diabetic patients after acute coronary syndrome based on insulin requirement. Eur Heart J. 2020;41:1552.","DOI":"10.1093\/ehjci\/ehaa946.1552"},{"key":"749_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100167","author":"W Ageno","year":"2023","unstructured":"Ageno W, Antonucci E, Poli D, Bucherini E, Chistolini A, Fregoni V, et al. Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes. Res Pract Thromb Haemost. 2023. https:\/\/doi.org\/10.1016\/j.rpth.2023.100167.","journal-title":"Res Pract Thromb Haemost"},{"key":"749_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1661-0283","volume":"42","author":"M Zdanyte","year":"2022","unstructured":"Zdanyte M, Rath D, Gawaz M, Geisler T. Venous Thrombosis and SARS-CoV-2. Hamostaseologie. 2022;42:240\u20137.","journal-title":"Hamostaseologie"},{"key":"749_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.chest.2022.02.006","volume":"162","author":"LK Moores","year":"2022","unstructured":"Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report. Chest. 2022;162:213\u201325.","journal-title":"Chest"},{"key":"749_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.thromres.2020.08.020","volume":"196","author":"A Porfidia","year":"2020","unstructured":"Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes AWS, Di Nisio M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020;196:67\u201374.","journal-title":"Thromb Res"},{"key":"749_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651545","volume":"12","author":"XZ Fang","year":"2021","unstructured":"Fang XZ, Wang YX, Xu JQ, He YJ, Peng ZK, Shang Y. Immunothrombosis in Acute Respiratory Dysfunction of COVID-19. Front Immunol. 2021;12: 651545.","journal-title":"Front Immunol"},{"key":"749_CR50","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura A, Vecchi\u00e9 A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21:319\u201329.","journal-title":"Nat Rev Immunol"},{"key":"749_CR51","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23:e334\u201347.","journal-title":"Lancet Oncol"},{"key":"749_CR52","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2147\/PPA.S112297","volume":"10","author":"P Vora","year":"2016","unstructured":"Vora P, Soriano-Gabarr\u00f3 M, Suzart K, Persson BG. Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies. Patient Prefer Adherence. 2016;10:1657\u201365.","journal-title":"Patient Prefer Adherence"},{"key":"749_CR53","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/a-1731-3922","volume":"122","author":"L Bertoletti","year":"2022","unstructured":"Bertoletti L, Gusto G, Khachatryan A, Quignot N, Chaves J, Moniot A, et al. Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France. Thromb Haemost. 2022;122:1384\u201396.","journal-title":"Thromb Haemost"},{"key":"749_CR54","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.jval.2018.09.683","volume":"21","author":"R Carroll","year":"2018","unstructured":"Carroll R, Lambrelli D, Donaldson R, Schultze A, Nordstrom B, Stynes G, et al. PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLAND (ISPOR Abstract). Value in Health. 2018;21:S115.","journal-title":"Value in Health"},{"key":"749_CR55","unstructured":"Dix C, Bortz H, da Gama M, Treloar M, Reynolds M, Day T, et al. PB0447 - Adherence and persistence to Direct Oral Anticoagulants (DOACs) in the community following newly diagnosed Venous Thromboembolism (VTE) \u2013 a pharmacy-linkage study [abstract]. https:\/\/abstracts.isth.org\/abstract\/adherence-and-persistence-to-direct-oral-anticoagulants-doacs-in-the-community-following-newly-diagnosed-venous-thromboembolism-vte-a-pharmacy-linkage-study\/ ISTH 2022 Congress. 2022. Accessed 08 Jan 2025."},{"key":"749_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.036","volume":"193","author":"A Packard","year":"2020","unstructured":"Packard A, Delate T, Martinez K, Clark NP. Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service. Thromb Res. 2020;193:40\u20134.","journal-title":"Thromb Res"},{"key":"749_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/jth.15153","volume":"19","author":"JK Schaefer","year":"2021","unstructured":"Schaefer JK, Li M, Wu Z, Basu T, Dorsch MP, Barnes GD, et al. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. J Thromb Haemost. 2021;19:212\u201320.","journal-title":"J Thromb Haemost"},{"key":"749_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.thromres.2015.07.007","volume":"136","author":"LA Castellucci","year":"2015","unstructured":"Castellucci LA, Shaw J, van der Salm K, Erkens P, Le Gal G, Petrcich W, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res. 2015;136:727\u201331.","journal-title":"Thromb Res"},{"key":"749_CR59","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/PPA.S131157","volume":"11","author":"I Keita","year":"2017","unstructured":"Keita I, Aubin-Auger I, Lalanne C, Aubert JP, Chassany O, Duracinsky M, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017;11:1625\u201334.","journal-title":"Patient Prefer Adherence"},{"key":"749_CR60","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2147\/PPA.S367105","volume":"16","author":"KO Bonsu","year":"2022","unstructured":"Bonsu KO, Young S, Lee T, Nguyen H, Chitsike RS. Adherence to Antithrombotic Therapy for Patients Attending a Multidisciplinary Thrombosis Service in Canada - A Cross-Sectional Survey. Patient Prefer Adherence. 2022;16:1771\u201380.","journal-title":"Patient Prefer Adherence"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00749-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T20:01:44Z","timestamp":1750708904000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00749-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00749-1","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed an informed consent document. The final protocol, any amendments, and informed consent documentation were reviewed and approved by an Institutional Review Board for each site participating in the study. The study was conducted in accordance with legal and regulatory requirements and followed generally accepted research practices described in the Guidelines for Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.Supported by Pfizer Hellas SA.PS, IS, IA and DM are employees of Pfizer and may hold stock or stock options. EM, SK, GP, EF, GN, OK, GT, KF, CS, KI, VT, NK, IS, IK, GM, KN, DC, DS, CK, KM, IV, CK, PT and SFN declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.ED reports receiving support from Boehringer and MSD for attending meetings and travels. AG reports receiving consulting fees from Bayer, Servier, Medtronic and Gore. FZ reports participating as principal investigator at Alexandra General Hospital where payments were made to institute and receiving consulting fees, receiving honoraria for lectures and support for attending meetings and travel from AstraZeneca, Daiichi, Eli-Lilly, Merck, Pfizer, Genesis-Pharma, Novartis, MSD, Roche and Gilead. KK reports receiving grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Elpen, GlaxoSmithKline, Menarini and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Elpen, GlaxoSmithKline, Guidotti, Menarini, Pfizer and Sanofi, payment for lectures, presentations, manuscript writing from Alector Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Chiesi, Elpen, Gilead, GlaxoSmithKline, Guidotti, Menarini, Pfizer and Sanofi, participating on a safety data monitoring board or advisory board of Chiesi and being a board member of GOLD Assembly. DS being a board member of Hellenic Angiological Society. HM reports participating at clinical trials of Pfizer, receiving consulting fees from Sanofi and Novartis, honoraria for lectures from Amgen, AstraZeneca, Novartis, Pfizer and Sanofi, support for attending international congresses with travel, accommodation and meeting expenses from Novartis, Sanofi and Vianex and being a board member of Hellenic Society of Atherosclerosis and Hellenic Stroke Organization. TP receiving honoraria for lectures from Pfizer, support for attending international congresses with travel, accommodation and meeting expenses from Pfizer and being general secretary of Hellenic Phlebology Society. FM reports receiving support from Pfizer and Bayer for attending meetings and travels.Disclosure forms provided by the authors are available with the full text of this article at supplementary.\nNo other potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}